3 years survival of patients with multiple myeloma.

<strong>Background:</strong> The survival of patients with multiple myeloma varies. Frequently we don’t identify the patients that could be cured with advanced therapies, nor even recognize those, in which we expect a long survival with the classic treatment measures. That’s why it is ne...

Full description

Bibliographic Details
Main Authors: Julio Dámaso Fernández Águila, Alexander García Blay, Luis Alberto Corona Martínez, Maritza Cabrera Zamora, Leovaldo Prieto Jiménez., Tamara Guerra Alfonso
Format: Article
Language:Spanish
Published: Centro Provincial de Información de Ciencias Médicas. Cienfuegos 2006-12-01
Series:Medisur
Subjects:
Online Access:http://medisur.sld.cu/index.php/medisur/article/view/214
id doaj-e41ca05b38e449fc96246f91f860585e
record_format Article
spelling doaj-e41ca05b38e449fc96246f91f860585e2021-08-27T02:16:44ZspaCentro Provincial de Información de Ciencias Médicas. CienfuegosMedisur1727-897X2006-12-01438132143 years survival of patients with multiple myeloma.Julio Dámaso Fernández ÁguilaAlexander García BlayLuis Alberto Corona MartínezMaritza Cabrera ZamoraLeovaldo Prieto Jiménez.Tamara Guerra Alfonso<strong>Background:</strong> The survival of patients with multiple myeloma varies. Frequently we don’t identify the patients that could be cured with advanced therapies, nor even recognize those, in which we expect a long survival with the classic treatment measures. That’s why it is necessary the study of prognosis factors to achieve an optimum stratification and to individualize the pattern to follow. <strong>Objectives:</strong> To determine the 3 years survival of the patients with multiple mieloma and the factors that influence it. <strong>Methods:</strong> A descriptive study of a series of cases of 50 patients with multiple mieloma. The socio-demographic characteristics were studied, as well as the clinic-humoral state, type of treatment and response to it, the over life curves were calculated by the estimates of Kaplan-Meier. A uni-varied analysis was made for which the patients were stratified in groups, that were compared through the long-rank method. A trust interval of 95% was accepted. <strong>Results:</strong>The total 3 years survival was of 37%. The 58% of the cases used the combination of Melfalan with Prednisona as initial therapeutic scheme. The 47,1% of the treated patients had a positive response to the chemotherapy. There were no alarming differences in response percentage and in survival among those who received Melfalan-prednisona and those who were treated with schemes that combined both drugs. The functional capacity reduction, the association to renal insufficiency, and not having response to treatment were the factors associated to an early mortality. <strong>Conclusions:</strong> The identification by means of this study of the factors related with the illness, would allow us to stratify the sick persons and to individualize its cares to improve the survival.<strong><br /></strong>http://medisur.sld.cu/index.php/medisur/article/view/214mieloma múltiplepronósticofactores de riesgo
collection DOAJ
language Spanish
format Article
sources DOAJ
author Julio Dámaso Fernández Águila
Alexander García Blay
Luis Alberto Corona Martínez
Maritza Cabrera Zamora
Leovaldo Prieto Jiménez.
Tamara Guerra Alfonso
spellingShingle Julio Dámaso Fernández Águila
Alexander García Blay
Luis Alberto Corona Martínez
Maritza Cabrera Zamora
Leovaldo Prieto Jiménez.
Tamara Guerra Alfonso
3 years survival of patients with multiple myeloma.
Medisur
mieloma múltiple
pronóstico
factores de riesgo
author_facet Julio Dámaso Fernández Águila
Alexander García Blay
Luis Alberto Corona Martínez
Maritza Cabrera Zamora
Leovaldo Prieto Jiménez.
Tamara Guerra Alfonso
author_sort Julio Dámaso Fernández Águila
title 3 years survival of patients with multiple myeloma.
title_short 3 years survival of patients with multiple myeloma.
title_full 3 years survival of patients with multiple myeloma.
title_fullStr 3 years survival of patients with multiple myeloma.
title_full_unstemmed 3 years survival of patients with multiple myeloma.
title_sort 3 years survival of patients with multiple myeloma.
publisher Centro Provincial de Información de Ciencias Médicas. Cienfuegos
series Medisur
issn 1727-897X
publishDate 2006-12-01
description <strong>Background:</strong> The survival of patients with multiple myeloma varies. Frequently we don’t identify the patients that could be cured with advanced therapies, nor even recognize those, in which we expect a long survival with the classic treatment measures. That’s why it is necessary the study of prognosis factors to achieve an optimum stratification and to individualize the pattern to follow. <strong>Objectives:</strong> To determine the 3 years survival of the patients with multiple mieloma and the factors that influence it. <strong>Methods:</strong> A descriptive study of a series of cases of 50 patients with multiple mieloma. The socio-demographic characteristics were studied, as well as the clinic-humoral state, type of treatment and response to it, the over life curves were calculated by the estimates of Kaplan-Meier. A uni-varied analysis was made for which the patients were stratified in groups, that were compared through the long-rank method. A trust interval of 95% was accepted. <strong>Results:</strong>The total 3 years survival was of 37%. The 58% of the cases used the combination of Melfalan with Prednisona as initial therapeutic scheme. The 47,1% of the treated patients had a positive response to the chemotherapy. There were no alarming differences in response percentage and in survival among those who received Melfalan-prednisona and those who were treated with schemes that combined both drugs. The functional capacity reduction, the association to renal insufficiency, and not having response to treatment were the factors associated to an early mortality. <strong>Conclusions:</strong> The identification by means of this study of the factors related with the illness, would allow us to stratify the sick persons and to individualize its cares to improve the survival.<strong><br /></strong>
topic mieloma múltiple
pronóstico
factores de riesgo
url http://medisur.sld.cu/index.php/medisur/article/view/214
work_keys_str_mv AT juliodamasofernandezaguila 3yearssurvivalofpatientswithmultiplemyeloma
AT alexandergarciablay 3yearssurvivalofpatientswithmultiplemyeloma
AT luisalbertocoronamartinez 3yearssurvivalofpatientswithmultiplemyeloma
AT maritzacabrerazamora 3yearssurvivalofpatientswithmultiplemyeloma
AT leovaldoprietojimenez 3yearssurvivalofpatientswithmultiplemyeloma
AT tamaraguerraalfonso 3yearssurvivalofpatientswithmultiplemyeloma
_version_ 1721189083417411584